| Literature DB >> 31744530 |
Aidana Amangaldiyeva1, Salima Davlidova1, Bauyrzhan Baiserkin2, Natalya Dzissyuk2, Jack DeHovitz3, Syed Ali4.
Abstract
Against the current global trends, in the former Soviet Union (FSU) countries HIV prevalence is on the rise. Visa-free movement across borders has facilitated migrant-associated HIV transmission within this region. Despite efforts from the governments to curtail the growing epidemic, there is still a serious need for the development of strategies that focus on high-risk behaviors and practices responsible for the continued transmission of HIV in this region. While governments of FSU countries have taken commendable steps in recent years to address hurdles at each step of the HIV care continuum, to ensure 100% antiretroviral treatment (ART) accessibility to people living with HIV (PLHIV), testing for HIV needs to be enforced widely in FSU countries. Stigma against people who inject drugs (PWID), men who have sex with men (MSM), migrants, and PLHIV need to be addressed. Finally, to avoid breaks in ART supply, FSU countries need to gain independence in funding HIV care so that the provision of ART to PLHIV is made available without interruption.Entities:
Keywords: ART; Former Soviet Union countries (FSU); HIV
Mesh:
Substances:
Year: 2019 PMID: 31744530 PMCID: PMC6865057 DOI: 10.1186/s12981-019-0251-1
Source DB: PubMed Journal: AIDS Res Ther ISSN: 1742-6405 Impact factor: 2.250
Fig. 1Political map of FSU countries showing location, total population, and HIV prevalence in each country. Population and HIV prevalence data were taken from, respectively, http://www.worldometers.info, and http://www.unaids.org/en/regionscountries/countries
Fig. 2HIV testing and treatment coverage by countries (%). The percentage of PLHIV who know their status (in blue), and those receiving ART (in orange) in FSU countries, as of 2017. The data were retrieved from http://aidsinfo.unaids.org/ on March 29, 2019. Abbreviations; RU, UA, BY, LT, KZ, KG, UZ, TJ, EE, MD, GE, AM, AZ, stand for, respectively; Russia, Ukraine, Belarus, Latvia, Kazakhstan, Kyrgyzstan, Uzbekistan, Tajikistan, Estonia, Moldova, Georgia, Armenia, and Azerbaijan
ART resistance recorded in FSU countries
| Country | No. isolates | Overall (%) | NRTI (%) | NNRTI (%) | PI (%) | References |
|---|---|---|---|---|---|---|
| Armenia | n/a | n/a | n/a | n/a | n/a | |
| Azerbaijan | 41 | 0 | 0 | 0 | 0 | |
| Belarus | n/a | n/a | n/a | n/a | n/a | |
| Georgia | 47 | 8.3 | 6.4 | 2.1 | 0 | |
| Estonia | 244 | 4.5 | 1.6 | 2.5 | 0.4 | |
| 56 | 0 | 0 | 0 | 0 | ||
| 145 | 5.5 | 2.8 | 2.1 | 2.8 | ||
| Kazakhstan | 85 | 0 | 0 | 0 | 0 | |
| Kyrgyzstan | n/a | n/a | n/a | n/a | n/a | |
| Latvia | 117 | 3.4 | 0.9 | 0.9 | 1.7 | |
| Lithuania | 27 | 3.7 | 3.7 | 0 | 0 | |
| Moldova | n/a | n/a | n/a | n/a | n/a | |
| Russia | 68 | 4.4 | 0 | 2.9 | 1.5 | |
| 44 | 4.5 | 2.3 | 2.3 | 0 | Direct Genbank Submission | |
| 62 | 4.8 | 0 | 4.8 | 0 | ||
| 41 | 7.3 | 4.9 | 0 | 2.4 | ||
| Tajikistan | n/a | n/a | n/a | n/a | n/a | |
| Turkmenistan | n/a | n/a | n/a | n/a | n/a | |
| Ukraine | 161 | 3.7 | 2.5 | 0.6 | 0.6 | |
| Uzbekistan | 139 | 0 | 0 | 0 | 0 |
https://hivdb.stanford.edu/page/surveillancemap/
Implemented regimes of antiretroviral therapy in FSU countries
| Country | Preferred | Alternative | Sources |
|---|---|---|---|
| Russia | TDF + 3TC (or FTC) + EFV | TDF + 3TC + NVP (or DTG) ABC + 3TC + NVP (or DTG, EFV) AZT + 3TC + EFV (or NVP, DTG) | [ |
| Ukraine | TDF + 3TC (or FTC) + EFV DTG (or EFV) + TDF (or FTC) | EFV + ABC (or AZT) + ЗTC NVP + AZT + ЗTC NVP + TDF + FTC NVP + ABC + ЗTC | [ |
| Belarus | TDF + 3TC (or FTC) + EFV | TDF + FTC (or 3TC) +NVP AZT + 3TC + NVP (or EFV) | [ |
| Latvia | Acute HIV: 3NRTI; OR NNRTI + 2NRTI; OR PI + 2NRTI; OR PI + NNRTI AIDS: PI + 2NRTI; OR 2PI + 2NRTI; OR PI + NNRTI + NRTI; OR 2PI + NNRTI + NRTI | [ | |
| Lithuania | ABA + 3TC + RAL (or DTG, DRV/r, DRV/c, LPV/r, LPV/c) TDF + FTC + RAL (or DTG, DRV/r, DRV/c, LPV/r, LPV/c) | ABA + 3TC + EFV TDF + FTC + EFV 3TC + AZT + RAL (or DTG, DRV/r, DRV/c, LPV/r, LPV/c) | [ |
| Kyrgyzstan | TDF + 3TC (or FTC) + EFV | AZT + 3TC + EFV (or NVP) TDF + 3TC (or FTC) + NVP ABC + 3TC + EFV (or NVP) TDF (or ABC) + 3TC (or FTC) + DTG TDF (or ABC) + 3TC (or FTC) + EFV TDF + FTC + RPV | [ |
| Kazakhstan | 3TC (or FTC) + TDF + EFV (or NVP) | 3TC + AZT + EFV (or NVP) 3TC (or FTC) + TDF + DTG (or NVP, EFV) | [ |
| Uzbekistan | TDF + 3TC (or FTC) + EFV | AZT + 3TC + EFV (or NVP) TDF + 3TC (or FTC) + NVP | [ |
| Tajikistan | AZT (or ABC) + 3TC + EFV (or NVP) TDF (or ABC) + FTC + EFV (or NVP) | AZT (or ABC) + 3TC + LPV/r; TDF (or ABC) + FTC + LPV/r | [ |
| Turkmenistan | Not available | Not available | |
| Estonia | Not available | Not available | |
| Moldova | TDF + FTC (or 3TC) +DTG (or EFV) ABC + 3TC + DTG (or EFV) | AZT + 3TC (or FTC) + ATV/r (or LPV/r, DRV/r) TDF + FTC (or 3TC) + ATV/r (or LPV/r, DRV/r) | [ |
| Georgia | TDF + 3TC (or FTC) + EFV | AZT + 3TC + EFV (or NVP) TDF + 3TC (or FTC) + DTG (or EFV, NVP) | [ |
| Armenia | TDF + 3TC (or FTC) + EFV TDF + 3TC (or FTC) + DTG | AZT + 3TC + EFV (or NVP) TDF + 3TC (or FTC) + EFV TDF + 3TC (or FTC) + NVP | [ |
| Azerbaijan | TDF + FTC + LPV/r AZT + 3TC + EFV | [ |
Achievement of UNAIDS 90–90–90 target (to diagnose 90% of all HIV-positive persons, provide ART for 90% of those diagnosed, and achieve viral suppression for 90% of those treated by 2020) by FSU countries
| Country | 90–90–90 targets achieved | Year | References |
|---|---|---|---|
| Armenia | 73–72–83 | 2018 | * |
| Azerbaijan | n/a–71–75 | 2018 | * |
| Belarus | 79–74–69 | 2018 | * |
| Georgia | 59–84–85 | 2018 | * |
| Estonia | 83–71–90 | 2018 | * |
| Kazakhstan | 88–66–65 | 2018 | * |
| Kyrgyzstan | 68–64–68 | 2018 | * |
| Latvia | 74–41–n/a | 2017 | |
| Lithuania | 82–30-82 | 2016 | |
| Moldova | 54–63–77 | 2018 | * |
| Russia | 81–45–75 | 2017 | |
| Tajikistan | 58–80–67 | 2018 | * |
| Turkmenistan | No data | ||
| Ukraine | 71–73–93 | 2018 | * |
| Uzbekistan | 83–43–83 | 2015 |
* https://aidsinfo.unaids.org/